FDA approves aminolevulinic acid hydrochloride as imaging agent for gliomas

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved aminolevulinic acid hydrochloride, known as ALA HCl, as an optical imaging agent indicated in patients with gliomas (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login